See today's BioWorld
To read the full story, subscribe or sign in.

HIM2? Zytiga prostate win may be just the start as test proceeds into development

June 6, 2017
By Randy Osborne
CHICAGO – For men with prostate cancer (PC), the already good news regarding Zytiga (abiraterone, Johnson & Johnson) that came out of the American Society of Clinical Oncology (ASCO) meeting may get even better, and soon.
BioWorld